Komori
Earnings4519CHUGAI PHARMACEUTICAL CO.,LTD.Pharmaceuticals

F. Hoffmann-La Roche's sales results for the third quarter of 2026

Chugai Pharmaceutical announced that F. Hoffmann-La Roche had published its sales results for January-September 2026. The release does not include specific figures such as sales or year-on-year changes.

Worth reading
—
Scored from 0 of 6 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Results for this period

Third quarterJanuary-September 2026
Results for this period
ItemDetails
Fiscal Period ClassificationThird quarter
Period CoveredJanuary-September 2026
Items this document does not state (36)
Accounting standardsConsolidated / non-consolidatedNet SalesOperating profitOrdinary incomeProfit attributable to owners of the parentNet income per shareOperating MarginEquity ratioTotal assetsNet assetsCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastRevision to Earnings ForecastAnnual Dividend ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogDepreciation and amortizationImpairment lossBreakdown of extraordinary income (loss)Disclosure regarding the going concern assumptionChange in accounting policyChanges in the scope of consolidationMaterial subsequent eventsAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-EndFactors Behind Changes in Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The release only states that the sales results were published and does not explain the reasons for changes in performance.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
F. Hoffmann-La Roche's sales results for the third quarter of 2026 | CHUGAI PHARMACEUTICAL CO.,LTD. (4519) timely disclosure | Komori